Clinical efficacy of bevacizumab combined with cisplatin regimen in the treatment of malignant pleural effusion in lung cancer patients
10.3872/j.issn.1007-385x.2018.11.016
- VernacularTitle:贝伐珠单抗联合顺铂治疗肺癌恶性胸水的临床疗效
- Author:
ANG Bing
1
;
WU Yue
2
;
ZHOU Caiyun
1
Author Information
1. Department of Oncology, the Central Hospital of Huludao
2. Shool of Statistics, Renmin University of China
- Publication Type:Journal Article
- Keywords:
Bevacizumab;
cisplatin;
lung cancer;
pleural effusion
- From:
Chinese Journal of Cancer Biotherapy
2018;25(11):1176-1179
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To compare the safety and efficacy of bevacizumab plus cisplatin and cisplatin alone in the treatment of malignant pleural effusion of lung cancer patients. Methods: From November 2014 to November 2017, 27 patients diagnosed with lung cancer complicated with malignant pleural effusion at the department of Oncology, the Central Hospital of Huludao, were enrolled in this study. Fourteen patients received bevacizumab plus cisplatin and thirteen patients received cisplatin alone. The clinical efficacy and adverse reactions were compared between the two groups. Results: There was no significant difference in the general condition between the two groups before treatment(P>0.05). The bevacizumab group had better short-term efficacy than the cisplatin group and the difference was statistically significant(92.9% vs 61.5%, P<0.05). The main adverse reactions during the treatment were bone marrow suppression and gastrointestinal discomfort, etc. The incidence of adverse reactions was similar between the two groups, with no statistically significant difference(P>0.05). Conclusion: Compared with cisplatin alone, bevacizumab combined with cisplatin has better shortterm efficacy in the treatment of lung cancer patients with malignant pleural effusion. The adverse reactions were quite similar.
- Full text:20181116.pdf
